← GLP-1 medications hub · Semaglutide · Tirzepatide
At 72 weeks, tirzepatide vs semaglutide produced 20.2% mean weight loss versus 13.7% in SURMOUNT-5, the first randomized head-to-head trial between them (NEJM, May 2025).
That ends a long run of indirect comparisons, and it is the most important data point in the 2026 obesity-medication landscape.
The number doesn’t settle the decision for you. Cost, cardiovascular history, side effect tolerance, genetic response, and what your insurance actually covers all bend the answer.
A patient with established heart disease has a different right answer than a 44-year-old with 60 pounds to lose and no comorbidities. A budget-conscious self-pay patient has a different answer again.
What you want to know is which drug you should take, and why.
Below we cover the mechanism difference, the SURMOUNT-5 numbers in depth, the side effect reality week by week, the 2026 cost map across four purchase paths, who each drug is best for, and what happens when you stop or switch drugs mid-protocol.
Generic names run alongside brand names throughout: tirzepatide (Mounjaro, Zepbound) and semaglutide (Ozempic, Wegovy, Rybelsus). We will not pad this article with “consult your doctor” disclaimers.
The Two Drugs at a Glance
Five brand names confuse almost every new patient. Know exactly what you’re comparing before the comparison starts.
Semaglutide is a GLP-1 receptor agonist. It comes in three FDA-approved forms:
- Ozempic: weekly injection for type 2 diabetes (0.25 to 2.0 mg)
- Wegovy: weekly injection for obesity (0.25 to 2.4 mg), plus an oral tablet approved December 2025 (50 mg daily)
- Rybelsus: daily oral tablet for T2D (3, 7, or 14 mg)
Off-label use of Ozempic for weight loss is common where insurance covers the diabetes indication but not the obesity one.
Tirzepatide is a dual GLP-1 and GIP receptor agonist. It comes in two FDA-approved forms, both weekly injections:
- Mounjaro: type 2 diabetes (2.5 to 15 mg)
- Zepbound: obesity (2.5 to 15 mg) and moderate-to-severe obstructive sleep apnea in adults with obesity (approved December 2024)
No oral tirzepatide exists as of April 2026. Eli Lilly’s oral small-molecule GLP-1, orforglipron (Foundayo), was FDA-approved April 1, 2026, but it is not tirzepatide and produces less weight loss (11.2% at 72 weeks).
Both drugs carry a boxed warning for thyroid C-cell tumors based on rodent data. Both are contraindicated in personal or family history of medullary thyroid carcinoma and MEN2.
The one-line mechanism difference: semaglutide activates one receptor; tirzepatide activates two. Why the extra receptor matters is the next section.
Mechanism: Why a Second Receptor Changes the Outcome
For decades, GIP was considered a weight-gain hormone. Animal studies showed GIP receptor agonism drove fat storage, so pharmaceutical interest focused on blocking it.
Then, the math changed. When GIP receptors activate simultaneously with GLP-1 receptors, the combined signal shifts from fat storage to fat mobilization. That insight produced tirzepatide.
Semaglutide does three things. It slows gastric emptying, which flattens post-meal glucose spikes and extends satiety.
It signals fullness through GLP-1 receptors in the hypothalamus and brainstem, which patients describe as the quieting of “food noise”, connected to the psychology around overeating and resultant weight gain. And it stimulates glucose-dependent insulin release while suppressing glucagon, improving blood sugar control without causing hypoglycemia.
Tirzepatide does all of that, plus two more things through GIP receptor activation.
In adipose tissue, GIP cooperates with insulin to enhance glucose and lipid clearance in the fed state and boost lipolysis in the fasted state.
If you want to understand how stress complicates this metabolic process, check out our guide on the link between cortisol and insulin resistance.
In brown adipose tissue, GIP upregulates thermogenic genes and raises energy expenditure. GIP receptors in skeletal muscle may also reduce protein breakdown during caloric restriction, part of why tirzepatide shows slightly better muscle preservation than semaglutide at matched weight loss.
The clinical signal matches the biology. In SURPASS-2, a head-to-head in T2D patients, tirzepatide 15 mg produced 11.2 kg weight loss versus 5.7 kg on semaglutide 1 mg (the T2D dose at the time, not the 2.4 mg obesity dose).
In SURMOUNT-1, tirzepatide 15 mg produced 20.9% weight loss over 72 weeks. The insulin sensitivity advantage for tirzepatide is larger than weight loss alone explains (Diabetes, Obesity and Metabolism, 2025), which suggests the GIP component does real metabolic work beyond appetite suppression.
One more mechanism detail. Both drugs appear to dampen the mesolimbic dopaminergic reward pathway, which is why many patients describe reduced cravings for alcohol, sweets, and ultra-processed food within the first month.
The JAMA Psychiatry 2025 semaglutide RCT in alcohol use disorder and observational data showing 50 to 56% lower AUD risk both point the same direction.
The verdict: GLP-1 alone suppresses hunger. GLP-1 plus GIP suppresses hunger and rewires fat metabolism. That is why tirzepatide pulls ahead on the scale in the tirzepatide vs semaglutide comparison.
Clinical Efficacy: The SURMOUNT-5 Numbers in Plain English
In SURMOUNT-5, 32% of tirzepatide patients lost at least 25% of their body weight. Only 16% of semaglutide patients did. That responder-rate framing tells you more about your odds than any mean number can.
The trial: SURMOUNT-5, published NEJM May 11, 2025. 751 adults with obesity and without type 2 diabetes, randomized across 32 US sites, 72 weeks.
Both drugs were titrated to maximum tolerated dose (tirzepatide 10 or 15 mg weekly; semaglutide 1.7 or 2.4 mg weekly). Baseline population: 45 years old on average, 65% female, BMI 39, mean weight 113 kg, 16 years of obesity history. Lilly-funded, open-label (the main methodological limitation).
The primary result: mean weight loss of 20.2% on tirzepatide versus 13.7% on semaglutide, a 6.5-percentage-point difference (95% CI -8.1 to -4.9, p<0.001). In absolute kilograms, 22.8 kg versus 15.0 kg. BMI reduction ran 8.0 versus 5.3 kg/m², and waist circumference dropped 18.4 cm versus 13.0 cm.
The responder rates are more decision-useful than the mean:
| Weight loss threshold | Tirzepatide | Semaglutide |
|---|---|---|
| At least 10% | 82% | 60% |
| At least 15% | 65% | 40% |
| At least 20% | 48% | 27% |
| At least 25% | 32% | 16% |
| At least 30% | 20% | 7% |
Tirzepatide roughly doubled the odds of hitting the 25% threshold and nearly tripled them at 30%.
What the headline hides: 13.7% weight loss on semaglutide is not a consolation prize. For a patient at 113 kg, that is 15 kg over 72 weeks, enough to reverse prediabetes in many cases, meaningfully reduce blood pressure, and improve sleep quality.
By any standard that isn’t “the other drug did more,” semaglutide is a health-transforming outcome.
Real-world results run lower. JAMA Internal Medicine analyzed 18,386 matched pairs in a retrospective EHR cohort and found tirzepatide at 15.3% and semaglutide at 8.3% weight loss at 12 months.
The SHAPE insurance-claims study found tirzepatide at 16.5% and semaglutide at 14.1% over one year. The gap between trial and real-world tirzepatide vs semaglutide outcomes comes mostly from discontinuation and under-titration: only 25.9% of tirzepatide users reach 15 mg in practice, versus 83.5% of semaglutide users reaching 2.4 mg in the trial.
Best for: readers whose goal is the largest possible weight loss and who can tolerate the full titration. Skip the tirzepatide-first logic if semaglutide is what your insurance covers; 13.7% is still a floor most weight-loss interventions can’t reach.
Side Effects and Tolerability: The Real Week-by-Week Experience
The nausea is real. What matters is when, how much, how long.
In the only head-to-head that exists, tirzepatide was slightly better tolerated than semaglutide. GI rates in SURMOUNT-5:
| Side effect | Tirzepatide | Semaglutide |
|---|---|---|
| Nausea | 40% | 44% |
| Diarrhea | 23% | 30% |
| Vomiting | 13% | 24% |
| Constipation | 18% | 24% |
| GI-related discontinuation | 2.7% | 5.6% |
The drug with the stronger mechanism had fewer GI-related dropouts. One hypothesis: concurrent GIP activation buffers GLP-1-induced nausea.
A Nature genetics paper (April 2026, n=27,885) identified GLP1R and GIPR variants predicting response and side-effect risk; people homozygous for risk alleles at both loci had 14.8-fold higher odds of tirzepatide vomiting. For the majority without those variants, tirzepatide is marginally easier.
Side effects cluster in the first 72 hours after each weekly injection and in the first 2 to 4 weeks of every dose escalation. Nausea peaks on days 1 to 3 and usually improves by day 4 or 5. By week 8 to 10 at a stable dose, most patients are asymptomatic. The last increase before maintenance is often the hardest week of the protocol.
Beyond nausea: reflux and sulfur-smelling burps, usually dose-related. Constipation builds over weeks; 2.5 to 3 L of daily water and 25 to 30 g of fiber usually prevent it. Fatigue during weeks 1 through 3 is common and resolves. Rapid weight loss produces facial volume changes (“Ozempic face”) and muscle loss, both partially preventable with slower titration and resistance training.
The serious warnings matter. Boxed warning for thyroid C-cell tumors (absolute contraindication with medullary thyroid carcinoma or MEN2). Rare but documented: pancreatitis (<0.2% in trials), gallbladder disease, gastroparesis, kidney injury from dehydration during heavy vomiting. Stop the drug and call a prescriber for severe persistent abdominal pain, uncontrolled vomiting, or sudden vision changes.
If your prior GLP-1 history has been rough, tirzepatide had slightly fewer GI discontinuations in the only direct tirzepatide vs semaglutide comparison. Individual variation still exceeds the between-drug difference, and genetics may explain why.
Dosing, Titration, and Finding Your Working Dose
Your working dose is the one that keeps you losing weight with side effects you can live with. That is rarely the maximum.
Standard titration for each drug:
| Week | Zepbound (tirzepatide) | Wegovy (semaglutide) |
|---|---|---|
| 1 to 4 | 2.5 mg weekly | 0.25 mg weekly |
| 5 to 8 | 5 mg weekly | 0.5 mg weekly |
| 9 to 12 | 7.5 mg weekly | 1.0 mg weekly |
| 13 to 16 | 10 mg weekly | 1.7 mg weekly |
| 17 to 20 | 12.5 mg weekly | 2.4 mg weekly (maintenance) |
| 21+ | 15 mg weekly (maximum) | 2.4 mg weekly |
Both schedules minimize GI side effects during escalation. Faster titration is possible on paper but usually produces enough nausea that patients stop. Slower titration is a legitimate option for GI-sensitive patients, with evidence that it improves long-term persistence.
If you’re losing 1 to 2 pounds per week at a sub-maintenance dose, there is no clinical reason to push higher just to hit a target number on the label. The SHAPE real-world study found 83.5% of semaglutide users reached 2.4 mg versus only 25.9% of tirzepatide users at 15 mg, and outcomes still favored tirzepatide. Many patients do well long-term at 5 to 10 mg tirzepatide or 1.0 to 1.7 mg semaglutide.
Microdosing has a real place for a subset of patients. Half-step titration or sub-threshold doses (1 to 2.5 mg tirzepatide; 0.05 to 0.25 mg semaglutide) help patients with GI sensitivity, hormonal complexity (PCOS, perimenopause), or cost constraints. Evidence is observational but growing. Compounded versions permit intermediate doses that branded pens don’t, which is where 503A prescriptions earn their flexibility in the tirzepatide vs semaglutide conversation.
Quick comparison: Wegovy’s titration is slower and lower-numbered; Zepbound’s climbs in 2.5 mg steps. The pace is comparable; the numbers look different because the drugs aren’t equipotent milligram-for-milligram.
Cost and Access in 2026: What You’ll Actually Pay
The same drug can cost you $1,400 or $99 a month depending on how you buy it.
Here is the actual 2026 cost table.
| Path | Semaglutide | Tirzepatide |
|---|---|---|
| Brand retail (list) | Wegovy ~$1,350/mo | Zepbound ~$1,060-1,200/mo |
| T2D brand (list) | Ozempic ~$900/mo | Mounjaro ~$1,020/mo |
| Direct-pay vials | NovoCare (varies) | LillyDirect $299-449/mo |
| Oral brand | Oral Wegovy $149/mo (intro) | None available |
| Compounded (503A telehealth) | $99-300/mo | $200-400/mo |
| Commercial savings card | as low as $25/mo | as low as $25/mo |
Three things surprise patients. Brand Zepbound is currently cheaper than brand Wegovy. Direct-pay vial programs (LillyDirect and NovoCare) unlock brand-name access at a third to half the pen price. Commercial insurance savings cards drop either drug to $25 per month, but they require commercial coverage; Medicare enrollees do not qualify.
Insurance coverage improved through 2025 and 2026 but remains patchy for the obesity indication. Self-insured employers commonly exclude weight-loss GLP-1s, and most Medicare plans still do.
Coverage is better for the diabetes indication, which is why off-label Ozempic or Mounjaro for weight loss remains common where a patient has prediabetes, comorbid metabolic syndrome, or struggles to manage belly fat. For the compounded-only cash-pay lane, our rankings of the best compounded tirzepatide pharmacies and best compounded semaglutide pharmacies apply the same 503A legal lens to each drug.
Compounded tirzepatide and semaglutide, dispensed by 503A pharmacies through telehealth platforms, are legal in April 2026 under specific conditions. Tirzepatide remains on the FDA shortage list. Semaglutide was removed in early 2025, but federal court injunctions have kept 503A patient-specific compounding operating. Verify any pharmacy you use holds PCAB accreditation, provides a batch Certificate of Analysis, and has licensed physician oversight.
Total-cost math over 72 weeks:
LillyDirect vials of tirzepatide around $5,000. Compounded semaglutide $1,700 to $5,000 depending on provider. Brand-name Wegovy retail without coverage, over $22,000.
Best for tight budget: compounded tirzepatide vs semaglutide via verified telehealth.
Best with insurance: brand-name with prior authorization.
Skip brand retail without insurance unless direct-pay vials are unavailable for your dose.
Who Should Choose Which, and Who Should Skip Both
Your cardiovascular history, goal weight, and budget matter more than the headline efficacy number.
Lean tirzepatide when:
- Maximum weight loss is the goal (target greater than 20%)
- You have T2D with significant insulin resistance (SURPASS-2: 11.2 kg tirzepatide vs 5.7 kg semaglutide)
- You have moderate-to-severe obstructive sleep apnea with obesity (Zepbound is the only FDA-approved pharmacotherapy)
- You plateaued on semaglutide after 12+ months
- You have MASH and need the drug with the strongest resolution data (SYNERGY-NASH: 44 to 62% resolution)
- Your insurance covers Zepbound or Mounjaro
- You tolerated the 2.5 mg starting dose well during a prior trial
Lean semaglutide when:
- You have established cardiovascular disease or high CV risk. SELECT (NEJM 2023, n=17,604) showed a 20% MACE reduction with semaglutide in overweight and obese adults without T2D. Tirzepatide has no equivalent outcomes trial yet.
- You have chronic kidney disease with T2D (FDA approval for Ozempic, January 2025)
- You have MASH and want the drug with the FDA indication today (Ozempic approval, August 2025)
- Cost is the primary constraint and compounded semaglutide is cheaper in your market
- You want an oral option. Rybelsus is approved for T2D at 3, 7, or 14 mg daily. Oral Wegovy (50 mg daily) was approved December 2025 at $149/month intro pricing with 16.6% weight loss at 64 weeks.
- You responded well to a prior GLP-1
Skip both if any of these apply:
- Personal or family history of medullary thyroid carcinoma or MEN2 syndrome (boxed warning; absolute)
- Active or prior pancreatitis (relative contraindication; discuss with a prescriber)
- Severe gastroparesis or active uncontrolled GI disease
- Pregnancy, planning pregnancy within two months, or breastfeeding
- Type 1 diabetes (not approved; hypoglycemia risk if on insulin)
- eGFR below 30 (tirzepatide exclusion in SURMOUNT-5)
- Recent cardiac event or NYHA Class IV heart failure
- Active suicidal ideation (trials excluded PHQ-9 scores of 15 or above)
If your tirzepatide vs semaglutide question is pure weight loss without comorbidities, tirzepatide wins on the numbers. If you have CV disease or want the cheapest functional path, semaglutide is the honest answer.
Switching, Maintenance, and Keeping the Weight Off
The hardest part isn’t week one. It is month 24, when you’re asking whether you can ever stop.
Switching from semaglutide to tirzepatide requires no washout. Take your last semaglutide dose on its normal injection day, wait seven days, then start tirzepatide at 2.5 mg regardless of prior dose.
Titrate at 4-week intervals. In prospective data, 87% tolerated the transition without significant GI symptoms and only 2% discontinued.
Patients who plateaued on semaglutide 2.4 mg often restart weight loss on tirzepatide 5 to 10 mg. Switching the other direction likely leads to regain (Dr. Sangeeta Kashyap, Cleveland Clinic).
Stopping produces regain. The STEP-1 extension (Wilding 2022) followed 1,961 patients for 52 weeks after discontinuing semaglutide 2.4 mg.
They regained roughly two-thirds of their weight loss. Net loss fell from 17.3% at week 68 to 5.6% at week 120.
The same pattern is expected for tirzepatide. Stopping without a plan is the biggest reason patients call GLP-1s a failure, especially for those already managing the overlap of PTSD and weight gain.
Maintenance dosing is under-studied but widely practiced. Many patients drop from peak to a lower dose once at goal (Wegovy 2.4 to 1.0 mg; Zepbound 15 to 5 mg) and sustain satiety with fewer side effects. Guidelines treat obesity as a chronic condition requiring indefinite treatment.
Protein and resistance training are the missing half. STEP-1 showed 39% of semaglutide weight loss was lean mass; SURMOUNT-1 showed roughly 25% with tirzepatide.
Target 1.2 to 1.6 g protein per kg of goal body weight, distributed across meals at 25 to 40 g each. Resistance-train 2 to 3 times per week using compound movements (squats, hip hinges, rows, presses).
Dr. Melanie Haines (Mass General) identified advanced age, female sex, and low protein intake as the biggest predictors of muscle loss. Two of those are actionable on your end.
The verdict: plan for maintenance before you reach goal weight. A sustainable lower dose plus resistance training and adequate protein beats a hero dose plus no plan.
The Bottom Line
Here is what the evidence says you should do.
For pure weight loss, tirzepatide produces roughly a third more loss on average and has a slightly cleaner GI discontinuation profile in the only head-to-head trial that exists.
That is the honest read of the 2025 tirzepatide vs semaglutide evidence, and it is why EASO 2025 guidelines treat both drugs as first-line with tirzepatide favored for obesity without CV disease.
Semaglutide remains the right call if you have established cardiovascular disease (SELECT data), chronic kidney disease with T2D, or MASH with an FDA indication today.
It is also the right call if cost or access leans that way, if you want an oral option, or if you already respond well to what you’re taking. A 13.7% weight loss is not a consolation prize. It is a health-transforming outcome by any non-comparative standard.
The drug is one variable. Your titration, your protein intake, your resistance training, your maintenance plan, your decision about what dose to stay at: those determine whether the result sticks. Pick the drug based on the evidence that applies to you, then build the protocol around it.
FAQ
Is tirzepatide better than semaglutide for weight loss?
On average, yes. In SURMOUNT-5, tirzepatide produced 20.2% mean weight loss versus 13.7% on semaglutide at 72 weeks. Responder rates favored tirzepatide at every threshold: 82% vs 60% for at least 10% loss, 32% vs 16% for at least 25%. Both remain the most effective weight-loss medications available.
What’s the difference between Ozempic and Wegovy?
Same drug (semaglutide), different doses, different FDA indications. Ozempic covers type 2 diabetes at 0.25 to 2.0 mg weekly. Wegovy covers obesity at 0.25 to 2.4 mg weekly, plus a 50 mg daily oral tablet approved December 2025. Off-label Ozempic for weight loss is common where insurance covers T2D but not obesity.
Can I switch from semaglutide to tirzepatide?
Yes, no washout needed. Take your last semaglutide dose on its normal day, wait seven days, then start tirzepatide at 2.5 mg regardless of prior dose. Titrate at 4-week intervals. In prospective data, 87% tolerated the switch without significant GI symptoms; 2% discontinued.
How much weight will I lose on each drug?
Trial averages: 20.2% on tirzepatide and 13.7% on semaglutide at 72 weeks (SURMOUNT-5). Real-world averages run lower because of discontinuation and under-titration: 13 to 18% on tirzepatide and 8 to 14% on semaglutide over 12 months. GLP1R and GIPR variants predict response.
Is compounded semaglutide the same as Ozempic or Wegovy?
Same active ingredient, different source. A 503A pharmacy prepares it, not Novo Nordisk. It is not FDA-approved as a finished product but remains legal under patient-specific compounding rules in April 2026 via federal court injunctions. Pricing runs $99 to $300 per month. Verify PCAB accreditation and a Certificate of Analysis per batch.
Will I gain the weight back if I stop?
Most people do. STEP-1 extension showed semaglutide patients regained two-thirds of their lost weight within a year of stopping, and cardiometabolic improvements largely reversed. The same pattern is expected for tirzepatide. Maintenance dosing plus 1.2 to 1.6 g/kg protein and resistance training 2 to 3 times weekly mitigates regain.
What’s the oral version of tirzepatide?
None exists. Lilly’s orforglipron (Foundayo), FDA-approved April 2026, is oral but not tirzepatide: 11.2% loss at 72 weeks, no food or water restrictions. Oral semaglutide is sold as Rybelsus (T2D) and oral Wegovy (50 mg daily, 16.6% loss at 64 weeks).
Decided on a molecule? Best Tirzepatide Online is the next page if tirzepatide won; Best Semaglutide Online if semaglutide did.